AliveDx Submits 510(k) Notification to the FDA for Innovative Vasculitis Test AliveDx has announced the submission of its 510(k) notification to the FDA for the MosaiQ AiPlex® Vasculitis test, enhancing diagnostic capabilities for autoimmune conditions.

AliveDx Submits 510(k) Notification to the FDA for Innovative Vasculitis Test #USA #AliveDx #Eysins #MosaiQ_AiPlex #Vasculitis_Test